Rol del enterocito en la dislipemia de la resistencia insulínica

Seshasai, 2011, Diabetes mellitus, fasting glucose, and risk of cause-specific death, N Engl J Med, 364, 829, 10.1056/NEJMoa1008862 Grimaldi, 1999, epidemiology of cardio-vascular complications of diabetes, Diabetes Metab, 25, 12 Baigent, 2010, Efficacy and safety of more intensive lowering of ldl cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 Adeli, 2008, Intestinal lipoprotein overproduction in insulin-resistant states, Curr Opin Lipidol, 19, 221, 10.1097/MOL.0b013e3282ffaf82 Barter, 2007, Hdl cholesterol, very low levels of ldl cholesterol, and cardiovascular events, N Engl J Med, 357, 1301, 10.1056/NEJMoa064278 Hokanson, 1996, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies, J Cardiovasc Risk, 3, 213, 10.1097/00043798-199604000-00014 Miller, 2008, Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the prove it-timi 22 trial, J Am Coll Cardiol, 51, 724, 10.1016/j.jacc.2007.10.038 Packard, 2006, Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease, Curr Opin Lipidol, 17, 412, 10.1097/01.mol.0000236367.42755.c1 Nordestgaard, 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women, JAMA, 298, 299, 10.1001/jama.298.3.299 LaRosa, 2005, Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 352, 1425, 10.1056/NEJMoa050461 Alipour, 2008, Novel aspects of postprandial lipemia in relation to atherosclerosis, Atheroscler Suppl, 9, 39, 10.1016/j.atherosclerosissup.2008.05.007 Curtin, 1996, Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein b-48, Acta Diabetol, 33, 205, 10.1007/BF02048544 Pal, 2003, Identification of lipoproteins of intestinal origin in human atherosclerotic plaque, Clin Chem Lab Med, 41, 792, 10.1515/CCLM.2003.120 Hogue, 2007, Evidence of increased secretion of apolipoprotein b-48-containing lipoproteins in subjects with type 2 diabetes, J Lipid Res, 48, 1336, 10.1194/jlr.M600548-JLR200 Schaefer, 2002, Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the framingham offspring study, Diabetes Care, 25, 989, 10.2337/diacare.25.6.989 Karpe, 1994, Postprandial lipoproteins and progression of coronary atherosclerosis, Atherosclerosis, 106, 83, 10.1016/0021-9150(94)90085-X Proctor, 2002, Arterial retention of apolipoprotein b(48)- and b(100)-containing lipoproteins in atherogenesis, Curr Opin Lipidol, 13, 461, 10.1097/00041433-200210000-00001 Innerarity, 1996, Biosynthesis of apolipoprotein b48-containing lipoproteins. Regulation by novel post-transcriptional mechanisms, J Biol Chem, 271, 2353, 10.1074/jbc.271.5.2353 van Greevenbroek, 1998, Chylomicron synthesis by intestinal cells in vitro and in vivo, Atherosclerosis, 141, S9, 10.1016/S0021-9150(98)00212-3 Kendrick, 2001, Superior role of apolipoprotein b48 over apolipoprotein b100 in chylomicron assembly and fat absorption: An investigation of apobec-1 knock-out and wild-type mice, Biochem J, 356, 821, 10.1042/0264-6021:3560821 Gleeson, 1999, The role of microsomal triglyceride transfer protein and dietary cholesterol in chylomicron production in diabetes, Diabetologia, 42, 944, 10.1007/s001250051252 Cohn, 1993, Contribution of apob-48 and apob-100 triglyceride-rich lipoproteins (trl) to postprandial increases in the plasma concentration of trl triglycerides and retinyl esters, J Lipid Res, 34, 2033, 10.1016/S0022-2275(20)35345-1 Adiels, 2008, Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome, Arterioscler Thromb Vasc Biol, 28, 1225, 10.1161/ATVBAHA.107.160192 Haffner, 1984, Retarded chylomicron apolipoprotein-b catabolism in type 2 (non-insulin-dependent) diabetic subjects with lipaemia, Diabetologia, 26, 349, 10.1007/BF00266035 Mamo, 1992, Hypertriglyceridemia is exacerbated by slow lipolysis of triacylglycerol-rich lipoproteins in fed but not fasted streptozotocin diabetic rats, Biochim Biophys Acta, 1128, 132, 10.1016/0005-2760(92)90298-A Bar-on, 1984, Removal defect of very-low-density lipoproteins from diabetic rats, Biochim Biophys Acta, 793, 115, 10.1016/0005-2760(84)90059-6 Brunzell, 1973, Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man, J Clin Invest, 52, 1578, 10.1172/JCI107334 Chan, 2002, Apolipoprotein b-100 kinetics in visceral obesity: Associations with plasma apolipoprotein c-iii concentration, Metabolism, 51, 1041, 10.1053/meta.2002.33339 Dasu, 2011, Free fatty acids in the presence of high glucose amplify monocyte inflammation via toll-like receptors, Am J Physiol Endocrinol Metab, 300, E145, 10.1152/ajpendo.00490.2010 Flood, 2002, Identification of the proteoglycan binding site in apolipoprotein b48, J Biol Chem, 277, 32228, 10.1074/jbc.M204053200 Varela, 2011, A high-fat meal promotes lipid-load and apolipoprotein b-48 receptor transcriptional activity in circulating monocytes, Am J Clin Nutr, 93, 918, 10.3945/ajcn.110.007765 Brown, 2000, A macrophage receptor for apolipoprotein b48: Cloning, expression, and atherosclerosis, Proc Natl Acad Sci U S A, 97, 7488, 10.1073/pnas.120184097 Nakano, 2008, Detection of apolipoproteins b-48 and b-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases, Clin Chim Acta, 390, 38, 10.1016/j.cca.2007.12.012 de Silva, 1994, Overexpression of human apolipoprotein c-iii in transgenic mice results in an accumulation of apolipoprotein b48 remnants that is corrected by excess apolipoprotein e, J Biol Chem, 269, 2324, 10.1016/S0021-9258(17)42171-5 Zhang, 1992, Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein e, Science, 258, 468, 10.1126/science.1411543 Lemieux, 1998, Apolipoprotein b-48 and retinyl palmitate are not equivalent markers of postprandial intestinal lipoproteins, J Lipid Res, 39, 1964, 10.1016/S0022-2275(20)32494-9 Lenich, 1987, Chylomicron remnant-vitamin a metabolism by the human hepatoma cell line hepg2, J Lipid Res, 28, 183, 10.1016/S0022-2275(20)38716-2 Phillips, 1997, A single copy of apolipoprotein b-48 is present on the human chylomicron remnant, J Lipid Res, 38, 1170, 10.1016/S0022-2275(20)37199-6 Welty, 2004, Interrelationships between human apolipoprotein a-i and apolipoproteins b-48 and b-100 kinetics using stable isotopes, Arterioscler Thromb Vasc Biol, 24, 1703, 10.1161/01.ATV.0000137975.14996.df Nogueira, 2012, Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes, Arterioscler Thromb Vasc Biol, 32, 1039, 10.1161/ATVBAHA.111.242073 Duez, 2006, Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein b-48-containing lipoproteins in humans, Arterioscler Thromb Vasc Biol, 26, 1357, 10.1161/01.ATV.0000222015.76038.14 Lopez-Miranda, 2007, Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism, Br J Nutr, 98, 458, 10.1017/S000711450774268X Lairon, 2008, Macronutrient intake and modulation on chylomicron production and clearance, Atheroscler Suppl, 9, 45, 10.1016/j.atherosclerosissup.2008.05.006 Haidari, 2002, J Biol Chem, 277, 31646, 10.1074/jbc.M200544200 Arbeeny, 1992, Inhibition of fatty acid synthesis decreases very low density lipoprotein secretion in the hamster, J Lipid Res, 33, 843, 10.1016/S0022-2275(20)41509-3 Liu, 1991, The association of hepatic apoprotein and lipid metabolism in hamsters and rats, Comp Biochem Physiol A Comp Physiol, 99, 223, 10.1016/0300-9629(91)90263-C Taghibiglou, 2000, J Biol Chem, 275, 8416, 10.1074/jbc.275.12.8416 Taghibiglou, 2002, Hepatic very low density lipoprotein-apob overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1b in a fructose-fed hamster model of insulin resistance, J Biol Chem, 277, 793, 10.1074/jbc.M106737200 Carpentier, 2002, Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster, J Biol Chem, 277, 28795, 10.1074/jbc.M204568200 Leung, 2004, Rosiglitazone improves intestinal lipoprotein overproduction in the fat-fed syrian golden hamster, an animal model of nutritionally-induced insulin resistance, Atherosclerosis, 174, 235, 10.1016/j.atherosclerosis.2004.02.005 Lewis, 2005, Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: Studies in the fructose-fed syrian golden hamster, Endocrinology, 146, 247, 10.1210/en.2004-1143 Zoltowska, 2003, Cellular aspects of intestinal lipoprotein assembly in psammomys obesus: A model of insulin resistance and type 2 diabetes, Diabetes, 52, 2539, 10.2337/diabetes.52.10.2539 Federico, 2006, Diabetes, 55, 1316, 10.2337/db04-1084 Avramoglu, 2006, Lipid and lipoprotein dysregulation in insulin resistant states, Clin Chim Acta, 368, 1, 10.1016/j.cca.2005.12.026 Duez, 2008, Dissociation between the insulin-sensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production, J Clin Endocrinol Metab, 93, 1722, 10.1210/jc.2007-2110 Nissen, 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med, 356, 2457, 10.1056/NEJMoa072761 Chan, 2002, Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity, Clin Chem, 48, 278, 10.1093/clinchem/48.2.278 Allister, 2006, Effect of an acute hyperinsulinaemic clamp on post-prandial lipaemia in subjects with insulin resistance, Eur J Clin Invest, 36, 489, 10.1111/j.1365-2362.2006.01651.x Alipour, 2011, Exploring the value of apob48 as a marker for atherosclerosis in clinical practice, Eur J Clin Invest, 41, 1365 Verseyden, 2002, Postprandial changes of apob-100 and apob-48 in tg rich lipoproteins in familial combined hyperlipidemia, J Lipid Res, 43, 274, 10.1016/S0022-2275(20)30169-3 Sundaram, 2010, Expression of apolipoprotein c-iii in mca-rh7777 cells enhances vldl assembly and secretion under lipid-rich conditions, J Lipid Res, 51, 150, 10.1194/M900346-JLR200 Evans, 2008, Tissue-specific stable isotope measurements of postprandial lipid metabolism in familial combined hyperlipidaemia, Atherosclerosis, 197, 164, 10.1016/j.atherosclerosis.2007.03.009 Brouwers, 2010, Novel drugs in familial combined hyperlipidemia: Lessons from type 2 diabetes mellitus, Curr Opin Lipidol, 21, 530, 10.1097/MOL.0b013e32833ea9ec Duez, 2008, Mechanism of intestinal lipoprotein overproduction in insulin resistant humans, Atheroscler Suppl, 9, 33, 10.1016/j.atherosclerosissup.2008.05.013 Drover, 2005, Cd36 deficiency impairs intestinal lipid secretion and clearance of chylomicrons from the blood, J Clin Invest, 115, 1290, 10.1172/JCI21514 Lally, 2006, Messenger rna levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: The role of niemann-pick c1-like 1, atp-binding cassette, transporters g5 and g8, and of microsomal triglyceride transfer protein, Diabetologia, 49, 1008, 10.1007/s00125-006-0177-8 Lewis, 2002, Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes, Endocr Rev, 23, 201, 10.1210/er.23.2.201 Duez, 2008, Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans, Circulation, 117, 2369, 10.1161/CIRCULATIONAHA.107.739888 Ota, 2008, Inhibition of apolipoprotein b100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents, J Clin Invest, 118, 316, 10.1172/JCI32752 Malmstrom, 1998, Effects of insulin and acipimox on vldl1 and vldl2 apolipoprotein b production in normal subjects, Diabetes, 47, 779, 10.2337/diabetes.47.5.779 Malmstrom, 1997, Defective regulation of triglyceride metabolism by insulin in the liver in niddm, Diabetologia, 40, 454, 10.1007/s001250050700 Pavlic, 2010, Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids, Diabetes, 59, 580, 10.2337/db09-1297 Theriault, 1992, Expression of apolipoprotein b in vitro in cell-free lysates of hepg2 cells: Evidence that insulin modulates apob synthesis at the translational level, Clin Biochem, 25, 321, 10.1016/0009-9120(92)80007-4 Harbis, 2001, Acute hyperinsulinism modulates plasma apolipoprotein b-48 triglyceride-rich lipoproteins in healthy subjects during the postprandial period, Diabetes, 50, 462, 10.2337/diabetes.50.2.462 Loirdighi, 1992, Insulin decreases chylomicron production in human fetal small intestine, Biochim Biophys Acta, 1175, 100, 10.1016/0167-4889(92)90015-4 Lewis, 1993, Effects of acute hyperinsulinemia on vldl triglyceride and vldl apob production in normal weight and obese individuals, Diabetes, 42, 833, 10.2337/diabetes.42.6.833 Aitman, 1997, Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia, Arterioscler Thromb Vasc Biol, 17, 748, 10.1161/01.ATV.17.4.748 Bourgeois, 1995, Vldl output by hepatocytes from obese zucker rats is resistant to the inhibitory effect of insulin, Am J Physiol, 269, E208 Longuet, 2008, The glucagon receptor is required for the adaptive metabolic response to fasting, Cell Metab, 8, 359, 10.1016/j.cmet.2008.09.008 Xiao, 2011, Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans, Diabetes, 60, 383, 10.2337/db10-0763 Hansen, 1995, Glucagon receptor mrna distribution in rat tissues, Peptides, 16, 1163, 10.1016/0196-9781(95)00078-X Thomsen, 1999, Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects, Am J Clin Nutr, 69, 1135, 10.1093/ajcn/69.6.1135 Qin, 2005, Glp-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats, Am J Physiol Gastrointest Liver Physiol, 288, G943, 10.1152/ajpgi.00303.2004 Hsieh, 2010, The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice, Diabetologia, 53, 552, 10.1007/s00125-009-1611-5 Meier, 2006, Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans, Diabetologia, 49, 452, 10.1007/s00125-005-0126-y Xiao, 2012, Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans, Arterioscler Thromb Vasc Biol, 32, 1513, 10.1161/ATVBAHA.112.246207 Matikainen, 2006, Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes, Diabetologia, 49, 2049, 10.1007/s00125-006-0340-2 Tremblay, 2011, Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes, Diabetes Obes Metab, 13, 366, 10.1111/j.1463-1326.2011.01362.x DeFronzo, 2008, Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study, Curr Med Res Opin, 24, 2943, 10.1185/03007990802418851 Hartmann, 2002, Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats, Regul Pept, 105, 173, 10.1016/S0167-0115(02)00013-7 Meier, 2006, Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans, Gastroenterology, 130, 44, 10.1053/j.gastro.2005.10.004 Hsieh, 2009, Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via cd36, Gastroenterology, 137, 1005 Qin, 2007, Tumor necrosis factor-alpha induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein b48-containing lipoproteins, Diabetes, 56, 450, 10.2337/db06-0518 Levy, 2006, Overproduction of intestinal lipoprotein containing apolipoprotein b-48 in psammomys obesus: Impact of dietary n-3 fatty acids, Diabetologia, 49, 1937, 10.1007/s00125-006-0315-3 Valdivielso, 2009, Omega 3 fatty acids induce a marked reduction of apolipoprotein b48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: A preliminary report, Cardiovasc Diabetol, 8, 1, 10.1186/1475-2840-8-1 Hogue, 2008, Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins b-100 and b-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia, Metabolism, 57, 246, 10.1016/j.metabol.2007.09.008 Castro Cabezas, 2004, Effects of atorvastatin on the clearance of triglyceride-rich lipoproteins in familial combined hyperlipidemia, J Clin Endocrinol Metab, 89, 5972, 10.1210/jc.2003-031329 Ooi, 2004, Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia, Atherosclerosis, 172, 375, 10.1016/j.atherosclerosis.2003.10.016 Tremblay, 2006, Effect of ezetimibe on the in vivo kinetics of apob-48 and apob-100 in men with primary hypercholesterolemia, Arterioscler Thromb Vasc Biol, 26, 1101, 10.1161/01.ATV.0000216750.09611.ec Tremblay, 2009, Effects of ezetimibe and simvastatin on apolipoprotein b metabolism in males with mixed hyperlipidemia, J Lipid Res, 50, 1463, 10.1194/jlr.P800061-JLR200 Mihas, 2011, Diagnostic value of postprandial triglyceride testing in healthy subjects: A meta-analysis, Curr Vasc Pharmacol, 9, 271, 10.2174/157016111795495530 Ooi, 2011, Proposing a “Lipemic index” As a nutritional and research tool, Curr Vasc Pharmacol, 9, 313, 10.2174/157016111795495594 Masuda, 2012, Correlation of fasting serum apolipoprotein b-48 with coronary artery disease prevalence, Eur J Clin Invest En Prensa, 10.1111/j.1365-2362.2012.02687.x